MKS Instruments Announces Proposed Private Offering of $1.0 Billion of Convertible Senior Notes
ANDOVER, Mass., May 13, 2024 (GLOBE NEWSWIRE) — MKS Instruments, Inc. (NASDAQ: MKSI) (“MKS”) today announced that it intends to […]
Fortrea Reports First Quarter 2024 Results
For the three months ended March 31, 2024, from continuing operations: Revenues of $662.1 million GAAP net loss of $81.6 […]
TSX News -
K92 Mining Announces Strong 2024 Q1 Financial Results – Financial Position Strong as Stage 3 Expansion Advances
VANCOUVER, British Columbia, May 13, 2024 (GLOBE NEWSWIRE) — K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQX: KNTNF) […]
Teleflex Publishes 2023 Global Impact Report
WAYNE, Pa., May 13, 2024 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today […]
Ducommun Incorporated Earns Northrop Grumman Missions Systems’ Platinum Supplier Designation
SANTA ANA, Calif., May 13, 2024 (GLOBE NEWSWIRE) — Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”), a global supplier of […]
Parsons Celebrates 80 Years of Infrastructure Excellence
CHANTILLY, Va., May 13, 2024 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) today celebrates Infrastructure Week, an annual event focused […]
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 […]
Olink reports first quarter 2024 financial results
UPPSALA, Sweden, May 13, 2024 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial […]
Here’s a Crazy And Clever Marketing Idea: Clothes That Actually Fit
CANTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) — Destination XL Group, Inc. (Nasdaq: DXLG), the largest integrated commerce specialty retailer […]
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights […]
